engineered bacteriophage T7

Engineered bacteriophage T7 refers to bacteriophage T7 viruses that have been genetically modified for therapeutic or diagnostic purposes. Modifications include display of targeting peptides or proteins on the phage capsid, integration of genes encoding therapeutic proteins (such as granulocyte macrophage colony-stimulating factor (GM-CSF) or antimicrobial peptides like apidaecin), or enabling payload delivery (such as CRISPR–Cas systems or reporters like lacZ). These engineered T7 phages can directly lyse bacterial cells, deliver therapeutic payloads (e.g., anti-tumor peptides, cytokines), or reprogram the tumor microenvironment by recruiting immune cells. In cancer models, engineered T7 displaying tumor-homing peptides and expressing GM-CSF inhibited tumor growth and attracted anti-tumor immune cells. In infectious disease models, T7 has been engineered to express antimicrobial peptides that kill resistant bacteria, and to deliver CRISPR systems for sequence-specific bacterial killing. Key mechanisms rely on phage infection of bacteria, engineered gene expression in targeted cells, and stimulation of immune or antimicrobial responses[1][2][3][4][5][6].

Other names

engineered phage T7recombinant bacteriophage T7genetically engineered T7 phage